FTRE

In October 2026, Barclays upgraded Fortrea's rating to Overweight and raised its price target to $23.00, leading to a 3.3% pre-market jump in shares. Fortrea announced its Q3 2026 earnings report for October 29, 2026, a week earlier than expected. In September 2026, Fortrea agreed to acquire Worldwide Clinical Trials' Early Phase Services division, aiming to enhance its early-phase trial footprint and diversify services, despite initial investor concerns about integration risks. Fortrea reinstated its CFO in September 2026 following a legal dispute with a former employer. Fortrea held its Q2 2026 earnings conference call on July 29, 2026. Kaskela Law Firm announced an investigation into Fortrea Holdings Inc. in July 2026. Fortrea unveiled its new AI-enhanced technology solutions, Fortrea Intelligent Technology™, in April 2026. The stock has shown high volatility and a significant increase of +101.1% over the past six months, reaching a 52-week high of $23.51 and a low of $8.55.